CME Group Inc. (NASDAQ:CME) Receives $222.73 Consensus PT from Analysts

CME Group Inc. (NASDAQ:CME) has been assigned an average recommendation of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $222.73.

A number of analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of CME Group from $210.00 to $233.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. The Goldman Sachs Group lifted their price objective on shares of CME Group from $195.00 to $198.00 and gave the stock a “sell” rating in a research note on Thursday, October 3rd. Redburn Atlantic lowered CME Group from a “buy” rating to a “neutral” rating and set a $244.00 target price for the company. in a research note on Tuesday, October 8th. Barclays boosted their price target on CME Group from $219.00 to $231.00 and gave the company an “equal weight” rating in a research note on Thursday, October 24th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on CME Group from $193.00 to $200.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th.

Insiders Place Their Bets

In related news, Director Bryan T. Durkin sold 7,593 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the completion of the transaction, the director now directly owns 55,607 shares in the company, valued at $11,932,706.13. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other CME Group news, CFO Lynne Fitzpatrick sold 754 shares of the firm’s stock in a transaction that occurred on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the sale, the chief financial officer now directly owns 13,261 shares of the company’s stock, valued at approximately $2,877,504.39. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bryan T. Durkin sold 7,593 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now directly owns 55,607 shares of the company’s stock, valued at approximately $11,932,706.13. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,621 shares of company stock worth $3,441,063. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On CME Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC purchased a new stake in shares of CME Group during the first quarter worth about $28,000. Y.D. More Investments Ltd purchased a new stake in CME Group during the 2nd quarter worth approximately $36,000. McClarren Financial Advisors Inc. lifted its position in shares of CME Group by 66.1% in the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock valued at $39,000 after acquiring an additional 78 shares in the last quarter. Asset Dedication LLC boosted its stake in shares of CME Group by 515.2% in the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock worth $40,000 after acquiring an additional 170 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in shares of CME Group by 62.2% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider’s stock worth $43,000 after purchasing an additional 74 shares in the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

CME Group Stock Performance

Shares of CME opened at $221.17 on Thursday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.09. The firm has a market cap of $79.64 billion, a PE ratio of 23.26, a P/E/G ratio of 5.62 and a beta of 0.55. CME Group has a 12 month low of $190.70 and a 12 month high of $230.36. The stock has a fifty day moving average price of $221.36 and a 200-day moving average price of $209.75.

CME Group (NASDAQ:CME) last released its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.03. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period last year, the business posted $2.25 earnings per share. The firm’s revenue was up 18.4% compared to the same quarter last year. Equities research analysts predict that CME Group will post 10.23 earnings per share for the current fiscal year.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.